Drugs / BRII-5395
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07557251 | Aug 2026 → Dec 2028 expected | hepatocellular carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRII-5395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557251 ↗ |
| Route | Intramuscular | “via IM injection” NCT07557251 ↗ |